Skip to content
Menu

B. Riley Securities Reiterates Buy on Cue Biopharma, Lowers Price Target to $25

Benzinga Newsdesk 1 day ago

Analyst RatingsNewsReiterationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

B. Riley Securities analyst Mayank Mamtani reiterates Cue Biopharma (NASDAQ:CUE) with a Buy and lowers the price target from $83 to $25.

B. Riley Securities analyst Mayank Mamtani reiterates Cue Biopharma (NASDAQ:CUE) with a Buy and lowers the price target from $83 to $25.

Read at benzinga.com